This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist approved for treating hypoactive sexual desire disorder in premenopausal women, enhancing sexual desire and satisfaction.
Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.
The most common adverse events were nausea, flushing, headache, and injection site reactions.
Adverse event-induced study discontinuation was significantly higher in the bremelanotide group compared to placebo.
Bremelanotide improved sexual satisfaction and related distress in premenopausal women.
Bremelanotide significantly increased sexual desire and reduced distress related to low sexual desire compared to placebo.
Stacks containing PT-141 (Bremelanotide)
Public community stacks that include this ingredient.